S&P Futures
4,294.75 -3.50 (-0.08%) Dow Futures
33,886.00 +13.00 (+0.04%) Nasdaq Futures
13,661.75 -19.50 (-0.14%) Russell 2000 Futures
2,023.90 +0.10 (+0.00%) Crude Oil
88.08 -1.33 (-1.49%) Gold
1,789.70 -8.40 (-0.47%)
Enveric Biosciences, Inc. (ENVB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.69 |
| Open | 6.71 |
| Bid | 0.00 x 2900 |
| Ask | 0.00 x 1000 |
| Day's Range | 6.45 - 6.89 |
| 52 Week Range | 5.90 - 187.00 |
| Volume | |
| Avg. Volume | 276,242 |
| Market Cap | 207.132M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.67 |
| Earnings Date | Nov 23, 2021 - Nov 24, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Apr 23, 2008 |
| 1y Target Est | 32.50 |
- Business Wire
Enveric Biosciences Appoints New Independent Directors
CAMBRIDGE, Mass., July 27, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has appointed three new independent directors, Michael D. Webb, President and CEO of CXL Ophthalmics, Bevin O'Neil, Chief Strategy Officer of ECRI, and Frank Pasqualone, recently retired Chief Business Officer of Theravance, to its Board of Directors.
- Business Wire
Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules
CAMBRIDGE, Mass., July 26, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 375,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof), priced at a premium to market under Nasdaq rules. In addition, the Company
- Business Wire
Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules
CAMBRIDGE, Mass., July 25, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has entered into a definitive agreement with an institutional investor for the purchase and sale of 375,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq
